Cargando…
Chemotherapy with cisplatin and paclitaxel in patients with locally advanced, recurrent or metastatic oesophageal cancer.
Single-agent therapy with paclitaxel is effective against both squamous cell carcinoma and adenocarcinoma of the oesophagus. However, only limited data are available on the combination of paclitaxel with other cytotoxic drugs in this entity. Patients with unresectable stage III, recurrent or metasta...
Autores principales: | Petrasch, S., Welt, A., Reinacher, A., Graeven, U., König, M., Schmiegel, W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063082/ https://www.ncbi.nlm.nih.gov/pubmed/9716036 |
Ejemplares similares
-
Phase II study of gemcitabine and cisplatin in locally advanced/metastatic oesophageal cancer
por: Millar, J, et al.
Publicado: (2005) -
Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer
por: Cho, Sang-Hee, et al.
Publicado: (2005) -
Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer
por: Polee, M B, et al.
Publicado: (2002) -
Effect of KRAS codon13 mutations in patients with advanced colorectal cancer (advanced CRC) under oxaliplatin containing chemotherapy. Results from a translational study of the AIO colorectal study group
por: Reinacher-Schick, Anke, et al.
Publicado: (2012) -
Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer
por: Li, Jing, et al.
Publicado: (2023)